Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
If any proof was needed that big money is still available for AI drug development, look no further than the 10-figure series B hauled in by Isomorphic Labs.
If any proof was needed that big money is still available for AI drug development, look no further than the 10-figure series B hauled in by Isomorphic Labs.